The telehealth platform Hims & Hers has officially launched its weight loss services in the United Kingdom. This move, which occurred on Thursday, represents the company’s second major international expansion in just over a week, following its recent debut in Canada on December 4th. This rapid geographic push underscores a deliberate strategy to capture growth in new markets.

Despite this aggressive growth, investor sentiment remains cautious. The company’s shares have faced selling pressure, largely due to concerns over potential regulatory changes in the United States. Reports suggesting possible stricter rules from the FDA or legislators regarding compounded GLP-1 medications have unsettled the market. Investors worry that new regulations could impact one of the firm’s fastest-growing business segments.

Consequently, the stock is trading well below the $40 threshold, even as fundamental performance remains robust. The market appears to be pricing in a „regulatory overhang“ that has not yet materialized. In Friday’s session, shares declined by 1.48% to $37.21, with trading volume exceeding 10 million shares.


Should investors sell immediately? Or is it worth buying Hims & Hers?

Diversifying Revenue Through International Reach

The launch in the UK provides British consumers with first-time access to Hims & Hers‘ personalized weight management programs, which include GLP-1-based pharmaceutical options. The strategic intent is clear: to diversify the company’s revenue base by entering markets with high demand for weight loss solutions. The operational figures support this growth narrative; third-quarter revenue surged by 49% year-over-year to reach $599 million.

Analyst Perspectives on the Path Forward

Market experts are divided on the near-term outlook. Barclays analyst Glen Santangelo expressed optimism, assigning a price target of $48 on December 9th, which implies significant upside from current levels. However, the broader analyst consensus remains tempered, largely maintaining a „hold“ recommendation until the regulatory uncertainty in the U.S. is resolved.

The Core Challenge: Growth Versus Uncertainty

The current situation presents a clear dichotomy. On one hand, Hims & Hers is demonstrating strong operational execution and rapid international expansion. On the other, its share price is being held back by fears of future regulatory action. This tension is likely to keep volatility elevated. Until there is greater clarity on the rules governing compounded medications in its home market, the stock is expected to oscillate between its fundamental strengths and perceived regulatory risks.

Ad

Hims & Hers Stock: Buy or Sell?! New Hims & Hers Analysis from December 13 delivers the answer:

The latest Hims & Hers figures speak for themselves: Urgent action needed for Hims & Hers investors.
Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 13.

Hims & Hers: Buy or sell?

Read more here…